文献速递肝病消化道肿瘤与早癌

野生型Kirsten大鼠肉瘤病毒癌基因是肝细胞癌的新型microRNA-622调控治疗靶点并参与索拉非尼耐药

Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
PubMed 文献 · Gut · 2017-12-23

该研究探讨野生型KRAS在肝细胞癌中的作用及作为治疗靶点的潜力。研究发现KRAS在肝癌中表达升高且与ERK激活、增殖、肿瘤大小和不良生存相关,是microRNA-622的直接靶点。抑制KRAS可抑制RAF/ERK和PI3K/AKT信号及增殖、促进凋亡,与索拉非尼联用有协同抗肿瘤作用,并可逆转索拉非尼耐药。

要点

  • 野生型KRAS在肝细胞癌中表达升高,与ERK激活、增殖率、肿瘤大小及患者不良生存相关。
  • KRAS是microRNA-622的直接靶点,该microRNA在肝癌中下调,其抑制增殖作用主要通过抑制KRAS介导。
  • 抑制KRAS可抑制RAF/ERK和PI3K/AKT信号及增殖、促进凋亡,与索拉非尼联用有协同抗肿瘤作用,并可使索拉非尼耐药细胞重新敏感。

核心结论

  • KRAS在肝细胞癌中因肿瘤抑制性microRNA-622缺失而失调,促进肿瘤进展并参与索拉非尼敏感性和耐药性。
  • 单独抑制KRAS或与索拉非尼联用似乎是有前景的肝细胞癌新型治疗策略。

研究设计与样本

  • 研究使用人肝细胞癌组织和细胞系进行表达和功能分析。
  • 新构建了索拉非尼耐药的肝细胞癌细胞。
  • 使用RNA干扰和新型小分子deltarasin在体外及小鼠同基因原位肝细胞癌模型中抑制KRAS。

主要发现

  • 肝细胞癌中野生型KRAS信使RNA和蛋白表达增加,并与细胞外信号调节激酶(ERK)激活、增殖率、晚期肿瘤大小和患者不良生存相关。
  • 生物信息学分析和报告基因检测显示KRAS是microRNA-622的直接靶点;该microRNA在肝细胞癌中下调,功能分析表明抑制KRAS是其抑制肝细胞癌增殖作用的主要介导机制。
  • 抑制KRAS在体外和体内均显著抑制RAF/ERK和PI3K/AKT信号及肝细胞癌细胞增殖,并增强凋亡。
  • 联合抑制KRAS与索拉非尼治疗在肝细胞癌中显示协同抗肿瘤效应。
  • 索拉非尼耐药肝细胞癌细胞显示KRAS表达升高,抑制KRAS使索拉非尼耐药细胞对增殖抑制和凋亡诱导重新敏感。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sorafenib is the only effective therapy for advanced hepatocellular carcinoma (HCC). Combinatory approaches targeting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)- and phosphatidylinositol-4,5-bisphosphate-3-kinase (PI3K)/protein-kinase B(AKT) signalling yield major therapeutic improvements. RAS proteins regulate both RAF/MAPK and PI3K/AKT signalling. However, the most important RAS isoform in carcinogenesis, Kirsten rat sarcoma (KRAS), remains unexplored in HCC. DESIGN: Human HCC tissues and cell lines were used for expression and functional analysis. Sorafenib-resistant HCC cells were newly generated. RNA interference and the novel small molecule deltarasin were used for KRAS inhibition both in vitro and in a murine syngeneic orthotopic HCC model. RESULTS: Expression of wild type KRAS messenger RNA and protein was increased in HCC and correlated with extracellular-signal regulated kinase (ERK) activation, proliferation rate, advanced tumour size and poor patient survival. Bioinformatic analysis and reporter assays revealed that KRAS is a direct target of microRNA-622. This microRNA was downregulated in HCC, and functional analysis demonstrated that KRAS-suppression is the major mediator of its inhibitory effect on HCC proliferation. KRAS inhibition markedly suppressed RAF/ERK and PI3K/AKT signalling and proliferation and enhanced apoptosis of HCC cells in vitro and in vivo. Combinatory KRAS inhibition and sorafenib treatment revealed synergistic antitumorigenic effects in HCC. Sorafenib-resistant HCC cells showed elevated KRAS expression, and KRAS inhibition resensitised sorafenib-resistant cells to suppression of proliferation and induction of apoptosis. CONCLUSIONS: KRAS is dysregulated in HCC by loss of tumour-suppressive microRNA-622, contributing to tumour progression, sorafenib sensitivity and resistance. KRAS inhibition alone or in combination with sorafenib appears as novel promising therapeutic strategy for HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Dietrich P, Koch A, Fritz V, et al. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2017. PMID: 29275358. doi:10.1136/gutjnl-2017-315402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。